{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T05:16:08Z","timestamp":1770959768432,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["643578"],"award-info":[{"award-number":["643578"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["FJC2018-036199-I"],"award-info":[{"award-number":["FJC2018-036199-I"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB\/TRR 57"],"award-info":[{"award-number":["SFB\/TRR 57"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012681","name":"Universit\u00e4tsklinikum K\u00f6ln","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012681","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with primary hyperoxaluria type I (PH I) are prone to develop early kidney failure. Systemic deposition of calcium-oxalate (CaOx) crystals starts, when renal function declines and plasma oxalate increases. All tissue, but especially bone, heart and eyes are affected. However, liver involvement, as CaOx deposition or chronic hepatitis\/fibrosis has never been reported. We examined liver specimen from 19 PH I patients (aged 1.5 to 52\u00a0years at sample collection), obtained by diagnostic biopsy (1), at autopsy (1), or transplantation (17). With polarization microscopy, birefringent CaOx crystals located in small arteries, but not within hepatocytes were found in 3\/19 patients. Cirrhosis was seen in one, fibrosis in 10\/19 patients, with porto-portal and nodular fibrosis (n\u2009=\u20091), with limitation to the portal field in 8 and\/or to central areas in 5 patients. Unspecific hepatitis features were observed in 7 patients. Fiber proliferations were detectable in 10 cases and in one sample transformed Ito-cells (myofibroblasts) were found. Iron deposition, but also megakaryocytes as sign of extramedullary erythropoiesis were found in 9, or 3 patients, respectively. Overall, liver involvement in patients with PH I was more pronounced, as previously described. However, CaOx deposition was negligible in liver, although the oxalate concentration there must be highest.<\/jats:p>","DOI":"10.1038\/s41598-022-19584-9","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T10:02:29Z","timestamp":1665050549000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Chronic liver disease and hepatic calcium-oxalate deposition in patients with primary hyperoxaluria type I"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0337-9613","authenticated-orcid":false,"given":"Pia","family":"Recker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0495-7670","authenticated-orcid":false,"given":"Bodo Bernhard","family":"Beck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5698-6863","authenticated-orcid":false,"given":"Przemyslaw","family":"Sikora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0171-7025","authenticated-orcid":false,"given":"Heike","family":"G\u00f6bel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9205-7906","authenticated-orcid":false,"given":"Markus Josef","family":"Kemper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6685-7267","authenticated-orcid":false,"given":"Angel","family":"Nazco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1139-4642","authenticated-orcid":false,"given":"Cristina","family":"Martin-Higueras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8120-3306","authenticated-orcid":false,"given":"Bernd","family":"Hoppe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,6]]},"reference":[{"key":"19584_CR1","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1056\/NEJMra1301564","volume":"369","author":"P Cochat","year":"2013","unstructured":"Cochat, P. & Rumsby, G. Primary hyperoxaluria. N. Engl. J. Med. 369, 649\u2013658 (2013).","journal-title":"N. Engl. J. Med."},{"key":"19584_CR2","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nrneph.2012.113","volume":"8","author":"B Hoppe","year":"2012","unstructured":"Hoppe, B. An update on primary hyperoxaluria. Nat. Rev. Nephrol. 8, 467\u2013475 (2012).","journal-title":"Nat. Rev. Nephrol."},{"key":"19584_CR3","first-page":"398","volume":"34","author":"V Lorenzo","year":"2014","unstructured":"Lorenzo, V., Torres, A. & Salido, E. Primary hyperoxaluria. Nefrologia Publicacion Oficial de la Sociedad Espanola Nefrologia 34, 398\u2013412 (2014).","journal-title":"Nefrologia Publicacion Oficial de la Sociedad Espanola Nefrologia"},{"key":"19584_CR4","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1681\/ASN.V1291986","volume":"12","author":"E Leumann","year":"2001","unstructured":"Leumann, E. & Hoppe, B. The primary hyperoxalurias. J. Am. Soc. Nephrol. 12, 1986\u20131993 (2001).","journal-title":"J. Am. Soc. Nephrol."},{"key":"19584_CR5","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/ki.2009.32","volume":"75","author":"B Hoppe","year":"2009","unstructured":"Hoppe, B., Beck, B. B. & Milliner, D. S. The primary hyperoxalurias. Kidney Int. 75, 1264\u20131271 (2009).","journal-title":"Kidney Int."},{"key":"19584_CR6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/0014-5793(86)80563-4","volume":"201","author":"CJ Danpure","year":"1986","unstructured":"Danpure, C. J. & Jennings, P. R. Peroxisomal alanine:glyoxylate aminotransferase deficiency in primary hyperoxaluria type I. FEBS Lett. 201, 20\u201324 (1986).","journal-title":"FEBS Lett."},{"key":"19584_CR7","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2215\/CJN.02810315","volume":"11","author":"F Zhao","year":"2016","unstructured":"Zhao, F. et al. Predictors of incident ESRD among patients with primary Hyperoxaluria presenting prior to kidney failure. Clin. J. Am. Soc. Nephrol. 11, 119\u2013126 (2016).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"19584_CR8","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/ki.2014.222","volume":"86","author":"G Mandrile","year":"2014","unstructured":"Mandrile, G. et al. Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type. Kidney Int. 86, 1197\u20131204 (2014).","journal-title":"Kidney Int."},{"key":"19584_CR9","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","volume":"384","author":"SF Garrelfs","year":"2021","unstructured":"Garrelfs, S. F. et al. Lumasiran, an RNAi therapeutic for primary Hyperoxaluria Type 1. N Engl J Med 384, 1216\u20131226 (2021).","journal-title":"N Engl J Med"},{"key":"19584_CR10","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1093\/hmg\/8.11.2063","volume":"8","author":"SD Cramer","year":"1999","unstructured":"Cramer, S. D., Ferree, P. M., Lin, K., Milliner, D. S. & Holmes, R. P. The gene encoding hydroxypyruvate reductase (GRHPR) is mutated in patients with primary hyperoxaluria type II. Hum Mol Genet 8, 2063\u20132069 (1999).","journal-title":"Hum Mol Genet"},{"key":"19584_CR11","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.kint.2019.08.018","volume":"96","author":"SF Garrelfs","year":"2019","unstructured":"Garrelfs, S. F. et al. Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up. Kidney Int. 96, 1389\u20131399 (2019).","journal-title":"Kidney Int."},{"key":"19584_CR12","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1111\/ajt.15829","volume":"20","author":"A del Bello","year":"2020","unstructured":"del Bello, A., Cointault, O., Delas, A. & Kamar, N. Primary hyperoxaluria type 2 successfully treated with combined liver-kidney transplantation after failure of isolated kidney transplantation. Am. J. Transplant 20, 1752\u20131753 (2020).","journal-title":"Am. J. Transplant"},{"key":"19584_CR13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/ajt.14418","volume":"18","author":"T Dhondup","year":"2018","unstructured":"Dhondup, T., Lorenz, E. C., Milliner, D. S. & Lieske, J. C. Combined liver-kidney transplantation for primary hyperoxaluria type 2: A case report. Am. J. Transplant 18, 253\u2013257 (2018).","journal-title":"Am. J. Transplant"},{"key":"19584_CR14","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.ajhg.2010.07.023","volume":"87","author":"R Belostotsky","year":"2010","unstructured":"Belostotsky, R. et al. Mutations in DHDPSL are responsible for primary hyperoxaluria type III. Am. J. Hum. Genet. 87, 392\u2013399 (2010).","journal-title":"Am. J. Hum. Genet."},{"key":"19584_CR15","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.2215\/CJN.02760311","volume":"6","author":"CG Monico","year":"2011","unstructured":"Monico, C. G. et al. Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis. Clin. J. Am. Soc. Nephrol. 6, 2289\u20132295 (2011).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"19584_CR16","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.kint.2021.03.031","volume":"100","author":"C Martin-Higueras","year":"2021","unstructured":"Martin-Higueras, C. et al. A report from the European Hyperoxaluria Consortium (OxalEurope) Registry on a large cohort of patients with primary hyperoxaluria type 3. Kidney Int. 100, 621\u2013635 (2021).","journal-title":"Kidney Int."},{"key":"19584_CR17","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2021.05.016","author":"P Singh","year":"2021","unstructured":"Singh, P. et al. Primary Hyperoxaluria Type 3 can also result in kidney failure: A case report. Am. J. Kidney Dis. https:\/\/doi.org\/10.1053\/j.ajkd.2021.05.016 (2021).","journal-title":"Am. J. Kidney Dis."},{"key":"19584_CR18","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1046\/j.1523-1755.1998.00891.x","volume":"53","author":"B Hoppe","year":"1998","unstructured":"Hoppe, B., Kemper, M. J., Hvizd, M. G., Sailer, D. E. & Langman, C. B. Simultaneous determination of oxalate, citrate and sulfate in children\u2019s plasma with ion chromatography. Kidney Int. 53, 1348\u20131352 (1998).","journal-title":"Kidney Int."},{"key":"19584_CR19","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1159\/000086359","volume":"25","author":"NV Jamieson","year":"2005","unstructured":"Jamieson, N. V. European PHI transplantation study group A 20-year experience of combined liver\/kidney transplantation for primary hyperoxaluria (PH1): The European PH1 transplant registry experience 1984\u20132004. Am. J. Nephrol. 25, 282\u2013289 (2005).","journal-title":"Am. J. Nephrol."},{"key":"19584_CR20","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s00467-012-2126-8","volume":"27","author":"R Hueppelshaeuser","year":"2012","unstructured":"Hueppelshaeuser, R. et al. Enteric hyperoxaluria, recurrent urolithiasis, and systemic oxalosis in patients with Crohn\u2019s disease. Pediatr. Nephrol. 27, 1103\u20131109 (2012).","journal-title":"Pediatr. Nephrol."},{"key":"19584_CR21","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1111\/j.1365-2133.2004.06247.x","volume":"151","author":"G Herrmann","year":"2004","unstructured":"Herrmann, G., Krieg, T., Weber, M., Sidhu, H. & Hoppe, B. Unusual painful sclerotic plaques on the legs of a patient with late diagnosis of primary hyperoxaluria type I. Br. J. Dermatol. 151, 1104\u20131107 (2004).","journal-title":"Br. J. Dermatol."},{"key":"19584_CR22","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/ki.1995.283","volume":"48","author":"M Marangella","year":"1995","unstructured":"Marangella, M. et al. Bony content of oxalate in patients with primary hyperoxaluria or oxalosis-unrelated renal failure. Kidney Int. 48, 182\u2013187 (1995).","journal-title":"Kidney Int."},{"key":"19584_CR23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.4103\/0970-1591.30276","volume":"23","author":"K Sriram","year":"2007","unstructured":"Sriram, K., Kekre, N. S. & Gopalakrishnan, G. Primary hyperoxaluria and systemic oxalosis. Indian J. Urol. 23, 79\u201380 (2007).","journal-title":"Indian J. Urol."},{"key":"19584_CR24","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.5858\/2002-126-1250-PHATL","volume":"126","author":"H Dimashkieh","year":"2002","unstructured":"Dimashkieh, H. & Koehler, A. Primary hyperoxaluria affecting the liver. Arch. Pathol. Lab. Med. 126, 1250\u20131251 (2002).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"19584_CR25","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1111\/j.1478-3231.2012.02845.x","volume":"32","author":"S Patra","year":"2012","unstructured":"Patra, S., Vij, M., Varghese, J. S. & Rela, M. Aggressive primary hyperoxaluria involving the liver in an adult. Liver Int. 32, 1564 (2012).","journal-title":"Liver Int."},{"key":"19584_CR26","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/ki.2009.350","volume":"77","author":"B Tanriover","year":"2010","unstructured":"Tanriover, B., Mejia, A., Foster, S. V. & Mubarak, A. Primary hyperoxaluria involving the liver and hepatic artery: Images of an aggressive disease. Kidney Int. 77, 651 (2010).","journal-title":"Kidney Int."},{"key":"19584_CR27","first-page":"184","volume":"50","author":"S Kazama-Saegusa","year":"1998","unstructured":"Kazama-Saegusa, S. et al. A case of late onset primary hyperoxaluria type I (PH-I) presented with black liver. Clin. Nephrol. 50, 184\u2013187 (1998).","journal-title":"Clin. Nephrol."},{"key":"19584_CR28","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1111\/hepr.12494","volume":"45","author":"T Kogiso","year":"2015","unstructured":"Kogiso, T. et al. Primary hyperoxaluria complicated with liver cirrhosis: A case report. Hepatol. Res. 45, 1251\u20131255 (2015).","journal-title":"Hepatol. Res."},{"key":"19584_CR29","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1046\/j.1523-1755.1999.00546.x","volume":"56","author":"B Hoppe","year":"1999","unstructured":"Hoppe, B. et al. Plasma calcium oxalate supersaturation in children with primary hyperoxaluria and end-stage renal failure. Kidney Int. 56, 268\u2013274 (1999).","journal-title":"Kidney Int."},{"key":"19584_CR30","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s004670050145","volume":"10","author":"B Hoppe","year":"1996","unstructured":"Hoppe, B. et al. Oxalate elimination via hemodialysis or peritoneal dialysis in children with chronic renal failure. Pediatr. Nephrol. 10, 488\u2013492 (1996).","journal-title":"Pediatr. Nephrol."},{"key":"19584_CR31","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1038\/sj.ki.5001806","volume":"70","author":"F Illies","year":"2006","unstructured":"Illies, F., Bonzel, K.-E., Wingen, A.-M., Latta, K. & Hoyer, P. F. Clearance and removal of oxalate in children on intensified dialysis for primary hyperoxaluria type 1. Kidney Int. 70, 1642\u20131648 (2006).","journal-title":"Kidney Int."},{"key":"19584_CR32","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S0022-5347(17)46073-3","volume":"135","author":"MJ Blumenfrucht","year":"1986","unstructured":"Blumenfrucht, M. J., Cheeks, C. & Wedeen, R. P. Multiorgan crystal deposition following intravenous oxalate infusion in rat. J. Urol. 135, 1274\u20131279 (1986).","journal-title":"J. Urol."},{"key":"19584_CR33","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.jhep.2010.07.036","volume":"54","author":"N Schnedler","year":"2011","unstructured":"Schnedler, N., Burckhardt, G. & Burckhardt, B. C. Glyoxylate is a substrate of the sulfate-oxalate exchanger, sat-1, and increases its expression in HepG2 cells. J. Hepatol. 54, 513\u2013520 (2011).","journal-title":"J. Hepatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-19584-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-19584-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-19584-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T10:11:00Z","timestamp":1665051060000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-19584-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,6]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["19584"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-19584-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,6]]},"assertion":[{"value":"25 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CMH is a consultant of Dicerna a NovoNordisk subsidiary, USA\/Denmark. BBB received consulting fees from Alnylam Pharmaceuticals, USA. BH has been an employee of Dicerna a NovoNordisk subsidiary, USA\/Denmark. The other authors have nothing to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16725"}}